Your browser doesn't support javascript.
loading
Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Kongtim, P; Adekola, K; Milton, D R; Ramlal, R; Jimenez, A; Chen, J; Rondon, G; Ahmed, S; Kebriaei, P; Betul, O; Hosing, C M; Popat, U; Khouri, I; Jabbour, E; Cortes, J E; Kantarjian, H M; Champlin, R E; Ciurea, S O.
Affiliation
  • Kongtim P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Adekola K; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Milton DR; Department of Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Ramlal R; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Jimenez A; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Chen J; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Rondon G; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Ahmed S; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Betul O; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Hosing CM; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Popat U; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Khouri I; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Jabbour E; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Cortes JE; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Kantarjian HM; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Champlin RE; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Ciurea SO; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Leukemia ; 31(7): 1654-1657, 2017 07.
Article in En | MEDLINE | ID: mdl-28400618
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein-Tyrosine Kinases / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Transplantation Conditioning / Graft Survival Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged Language: En Journal: Leukemia Year: 2017 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein-Tyrosine Kinases / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Transplantation Conditioning / Graft Survival Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged Language: En Journal: Leukemia Year: 2017 Document type: Article